Preview

The Russian Archives of Internal Medicine

Advanced search

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA

https://doi.org/10.20514/2226-6704-2016-6-1-45-48

Abstract

There were examined 86 patients aged 20 to 65 years with a diagnosis of bronchial asthma (BA). The objective is to evaluate the level of disease control, to study the effectiveness, safety and usability when used Foster (beclomethasone dipropionate and formoterol fumarate fixed combination) Combination and Foradil (formoterol fumarate and budesonide in free combination). Patients were divided into 2 groups randomly. The first group received Foster (beclomethasone dipropionate and formoterol fumarate in a fixed combination), and the second group — Foradil Combi (budesonide and formoterol fumarate in a free combination). Results of the study were assessed for 11-13 days and 3 months. The treatment showed a significant reduction in the severity of clinical symptoms in groups 1 and 2. Respiratory function after 3 months in group 1 improved to 17,4 ± 3,2% (p <0.05), and the second at 6,0 ± 3,3% (p> 0.1). Full control of the disease was achieved in one group, 48.83% of patients, and the second at 44.19% of the patients.

About the Authors

V. A. Nikitin
Voronezh state medical University N.N. Burdenko, Voronezh, Russia
Russian Federation


O. A. Lepuchova
Voronezh state medical University N.N. Burdenko, Voronezh, Russia
Russian Federation


L. V. Vasilieva
Voronezh state medical University N.N. Burdenko, Voronezh, Russia
Russian Federation


E. P. Karpuchina
Voronezh state medical University N.N. Burdenko, Voronezh, Russia
Russian Federation


References

1. Riddle H.C., Taylor D.R., Bateman E. et al., On behalf of the Working Group of the American Thoracic Society (NSS), the European Respiratory Society (EPO) for the control of asthma and its exacerbation. Treatment of asthma and its exacerbation: standardized final figures for clinical studies on asthma and clinical practice. White Paper ATO/EPO. Part 1. Pulmonary. 2011; (1): 19-40.

2. Revyakina V.A. Current approaches to the treatment of patients with bronchial asthma. Practical pulmonology. 2014; (1): 83-88.

3. Avdeev S.N. Fundamentals of inhalation therapy. Dosage aerosol inhalers. Asthma and allergy. 2013; (4): 2-7.

4. Avdeev S.N., Grigoriev E.V. Clinical and pharmacoeconomic aspects of Russia's Good clinical practice. 2011; (3): 2-7.

5. .Mescherekova N.N. Belevsky A.S. The possibility of using extra fine fixed combination of beclomethasone and formoterol in a single inhaler as maintenance therapy isimptomaticheskoy. Practical pulmonology. 2015; (1): 88-92.

6. Chuchalin A.G., Aysanov Z.R., Belevsky A.S. and others. The Russian Federal Respiratory Society guidelines for the diagnosis and treatment of asthma. Pulmonary .2014; (2): 5-11.

7. Budnevsky A.V., Kozhevnikov S.A., Burlachuk V.T., et al. Role of individual training programs to achieve asthma control. Pulmonology. 2013; (1): 54-58.

8. Bousquet J, Jeffery P.K., Busse W.W. et. al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J.Respir. Crit. Care Med. 2000; 161 (5): 1720-1745.

9. Barner P.J. Scientific rationale for using single inhaled for asthma control. Eur. Respir. J. 2007; (2): 34-38.

10. Braman S. The global burden of asthma. Chest. 2006; (130): 4-12.

11. Taylor D.R., Bateman E.D., Boulet L.-P. et. al. A new perspective on concepts of asthma severity and control. EUR. Respir.J. 2008; (32): 545-554.

12. Global Strategy for Asthma Management and Prevention? Global Initiative for Asthma (GINA). Update 2014 http: www.ginasthma.org.

13. Cochrane M.G. et. al. Chest. 2000; 117 (2): 542.


Review

For citations:


Nikitin V.A., Lepuchova O.A., Vasilieva L.V., Karpuchina E.P. COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA. The Russian Archives of Internal Medicine. 2016;6(1):45-48. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-1-45-48

Views: 24905


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2226-6704 (Print)
ISSN 2411-6564 (Online)